Compare HROW & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | TRS |
|---|---|---|
| Founded | 1998 | 1986 |
| Country | United States | United States |
| Employees | 373 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2004 |
| Metric | HROW | TRS |
|---|---|---|
| Price | $38.00 | $40.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $69.86 | $41.50 |
| AVG Volume (30 Days) | ★ 614.5K | 331.3K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.44% |
| EPS Growth | N/A | ★ 400.00 |
| EPS | N/A | ★ 21.40 |
| Revenue | N/A | ★ $645,720,000.00 |
| Revenue This Year | $31.62 | $5.42 |
| Revenue Next Year | $50.77 | $4.27 |
| P/E Ratio | ★ N/A | $1.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.54 | $30.43 |
| 52 Week High | $54.98 | $45.43 |
| Indicator | HROW | TRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 43.98 |
| Support Level | $37.81 | $39.24 |
| Resistance Level | $41.94 | $41.84 |
| Average True Range (ATR) | 2.28 | 1.08 |
| MACD | -0.87 | -0.17 |
| Stochastic Oscillator | 6.61 | 33.72 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.